Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on February 16, 2017, regarding events occurring on February 15, 2017. The filing addresses corporate governance changes specifically related to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive appointments and compensation arrangements.
Material Changes
The primary material change reported is the appointment of Suzanne Bruhn as a Class I director, effective February 15, 2017. The Board also granted her specific compensatory arrangements:
- Cash Retainer: $35,000 per year.
- Stock Option: Option to purchase 82,000 shares of common stock at an exercise price of $5.04 per share.
- Vesting Schedule: Monthly vesting over three years, contingent on continued service.
- Indemnification: Ms. Bruhn entered into the Company's standard form of indemnification agreement.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding business operations or financial performance. It explicitly states there are no undisclosed arrangements or material interests related to Ms. Bruhn's appointment.
Investor Verification Checklist
- Verify the correct registrant name is Aeglea BioTherapeutics, Inc., not Spyre Therapeutics, Inc.
- Confirm the total number of outstanding shares to assess the dilution impact of the 82,000 new options.
- Review the Company's existing compensation policy for non-employee directors to ensure the $35,000 retainer is consistent with prior practices.
- Check the stock price on February 15, 2017, to evaluate the intrinsic value of the $5.04 exercise price.